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In replantations and in free microvascular flap
reconstructive surgery, the possibilities for harvest
and use autologous vein grafts are often good.
However, during recent years, technical and surgical
skills have improved greatly and more difficult cases
are being submitted for these kinds of surgical treat-
ment. In patients with severe extremity traumas or
multifactorial vessel diseases, the limited access of
autologous vessel grafts increases the need for a
small-diameter artificial vessel graft, which is usable
in veins and in arteries. Although artificial vessel
grafts have been widely used in vascular surgery,
their clinical use in small-diameter arteries and for
venous replacement has been limited mainly because
of problems with graft occlusion. In particular,
smaller venous grafts have not been sucessful and are
not used in clinical work. A characterizaton of fac-
tors that influence graft patency in the venous sys-
tem is therefore of considerable interest.
In a previous study with the rabbit, we showed a
10-fold reduction of thrombus mass weight in
expanded polytetrafluoroethylene (PTFE) grafts
inserted into the aorta when dextran-70 isovolemic
hemodilution was used.1 The study suggested that
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the inhibitory effects on thrombus formation were
not related to the increased blood flow conditions
but to dextran-specific effects on the hemostatic
mechanisms. The first aim of the present investiga-
tion was to extend the studies of the effects of dex-
tran hemodilution on thrombus formation to artifi-
cial grafts in the venous system to explore whether
dextran could improve the success rate in artificial
venous grafts. 
Prolonged systemic or local heparin treatments
have been reported to improve the patency rates of
venous grafts.2,3 However, this approach is not easi-
ly used clinically in combination with surgery. A sin-
gle injection of heparin alone has not been success-
ful in inhibiting artificial graft thrombosis.3 Because
the data regarding the interaction between heparin
and dextran in these conditions are sparse, a second
aim of the study was to determine whether a bolus
dose of heparin could be effective in the artificial
venous graft system when used in combination with
dextran hemodilution. 
The thromboprophylactic action of dextran is mul-
tifactorial, and the exact processes involved are not
known.4-9 Dextran hemodilution reduces the levels of
coagulation factor VIIIR:Ag or von Willebrand’s fac-
tor, which influences hemostasis.5,10-13 Desmopressin
(DDAVP, 1-desamino-8-D-arginine vasopressin) has
been shown to counteract some of the effects of dex-
tran12-13 by increasing factor VIII:C and VIIIR:Ag.
DDAVP often is used before surgery in clinical prac-
tice to reduce bleeding. Therefore, as the third objec-
tive of the study, we examined the effects of DDAVP
in the rabbit model system to obtain information on
whether the effects of dextran are mediated by influ-
ences on factor VIII and to determine whether the use
of DDAVP influences the potentially beneficial effects
of dextran hemodilution on thrombosis in artificial
venous grafts.
MATERIALS AND METHODS
New Zealand rabbits of either sex were used in
this study. The project was approved by the local ani-
mal ethics committee, and the animal keepers at the
stables in the Department of Experimental Research,
Malmö University Hospital, professionally cared for
the animals.
The experiments began with an anesthetic proce-
dure previously described.1 An intramuscular injection
of 1 mg/kg body weight midazolam (Dormicum,
Roche, Sweden) was followed after 10 minutes by an
intramuscular injection of 0.3 mL/kg body weight of
fluanisone and 0.2 mg/mL fentanyl (Hypnorm,
Janssen, Pharmaceutica Beerse, Belgium). The
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catheters were placed in a marginal ear vein and in the
carotid artery. The arterial catheter was used to moni-
tor the arterial blood pressure and to withdraw blood
during hemodilution. The animals were placed on a
heating pad, and the rectal temperature was monitored
during the operation.
Before we initiated the series of experiments
included in the present study, we performed the
operative procedure on 4 rabbits to secure a reliable
technique for graft insertion. These animals were
not included in the study. Operations that were per-
formed with 1 dose of anesthesia and that had vessel
occlusion times that did not exceed 30 minutes were
found to result in a better and faster recovery after
the operation. Therefore, we used these relatively
short occlusion times in all rabbits. 
The infrarenal part of the vena cava was exposed
with careful dissection after the opening of the
abdomen with a mid-line incision. A probe (2.0-mm
inner diameter) of an ultrasonic Doppler flow meter
(Transonic TC 101 D, Transonic Inc, Ithaka, NJ)
was placed around the vena cava about 10 to 20 mm
proximal to the bifurcation. After stabilization of the
flow signal, at about 15 minutes, initial values for the
blood flow and for the blood pressure (via the arte-
rial catheter) were recorded. The animals underwent
treatment, in random order, according to 1 of the
following 6 protocols:
1. Control animals (n = 8) underwent no treatment
other than the insertion of the PTFE graft.
2. These animals (n = 8) underwent isovolemic
hemodilution with isosmotic dextran (Mw
70,000 Macrodex, Medisan, Sweden; containing
60 g/L dextran in physiologic NaCl). In this
group, 10 mL blood/kg body weight was
removed through the arterial catheter and simul-
taneously replaced with an equal volume of the
dextran solution through the venous catheter.
The hemodilution procedure lasted about 5 min-
utes and was similar to that used in previous
studies.1,14
3. These animals (n = 10) underwent isovolemic
hemodilution with isosmotic dextran as in the
group above (10 mL dextran solution/kg body
weight), with the addition of 1 intravenous (iv)
bolus injection of unfractioned heparin
(Pharmacia & Upjohn, 160 IU/kg body weight)
that was given immediately before the declamp-
ing of the graft.
4. These animals (n = 8) underwent treatment with
an iv bolus of heparin that was given as in group
3 but without hemodilution.
5. These animals (n = 9) underwent isovolemic dex-
tran hemodilution, with the same volumes and
procedures as in group 2 but with the addition of
1 iv bolus injection of DDAVP (Minirin Ferring,
Sweden; 0.4 m g/kg body weight), which was
administered immediately before reperfusion of
the graft.
6. These animals (n = 8) were treated as in group 3
but observed for 2 weeks instead of 48 hours as
in all other groups. In group 6, 1 animal died of
bleeding during the first postoperative hour. We
considered this to be caused by a technical failure
in the suturing of the anastomosis. Therefore,
this animal was excluded from the analysis.
The blood flow of the vena cava was recorded
continuously during the hemodilution procedures
and for an additional 15 minutes. Stable recordings
of the flow and the blood pressure at the end of this
period were taken as the representative values after
hemodilution.
Artificial vessel grafts were inserted in the vena
cava of all animals according to a procedure used for
the aortas of rabbits.1 Clamps were placed around
the vena cava about 20 mm proximal to the bifurca-
tion. The position of the clamps was chosen so that
no vessel branches were located between the clamps.
The vena cava was cut transversely between the
clamps, which left 3-mm to 4-mm vessel ends for the
subsequent suturing of the vessel graft. A PTFE graft
(GoreTex, Gore and Associates Inc, Elkton, Md),
which was 11 mm in length and had an inner diam-
eter of 3 mm, was cut, weighed, and kept in saline
solution. The graft was inserted into the vena cava by
end-to-end anastomoses with interrupted suturing
with 7-0 GoreTex (Gore and Associates Inc) sutures.
Twelve sutures were placed at each anastomosis.
After clamp removal, the flow probe was again placed
around the vessel on the cranial side of the graft at
the location where the previous recordings were
made. The blood flow and blood pressure were
recorded for 30 minutes. In all animals, the blood
flow remained stable during this observation period,
and the recording at the end of the period was used
as representative for the postoperative flow. The
abdomen was closed in 2 layers, and the animals were
allowed to awaken and return to their cages.
After 2 days, or after 2 weeks in group 6, the ani-
mals again underwent anesthesia, as described above.
The abdomen was opened, and the blood flow of the
vena cava was recorded in all animals in which the
graft was patent. The graft was identified, dissected
free, and cut at the anastomoses. The amount of
thrombus material in the graft was determined as
previously described.1 The graft was removed from
the animal and, as quickly as possible (within 15 sec-
onds), gently blotted between 2 sheets of gauze. The
graft was then weighed and opened longitudinally.
The inner surface was scraped to remove thrombus
aggregates, and the graft was again weighed. The
amount of thrombus formation was calculated as the
difference between the 2 weights. The animals were
killed with an overdose of pentobarbital (Mebumal
Vet, ACO Läkemedel AB, Sweden). Hematocrit val-
ues were initially obtained after hemodilution and
before the removal of the graft.
Statistics. All values are given as the mean ±
standard error of the mean, with the number of
observations given within parenthesis. Statistical
comparisons were made according to the Student’s
t-test for unpaired data, unless stated otherwise, or
the Bonferroni method when more than 2 means
were compared.
RESULTS
All animals included in the study tolerated the
operative procedure well. Also, no signs of poor cir-
culation, impaired leg mobility, or altered well-being
were observed in the animals in which the vena cava
was found to be completely occluded. For the 6
experimental groups in the study, the animal weights
and the initial hematocrit values are given in Table I.
No significant differences were observed between
the groups regarding these baseline parameters.
After hemodilution, the hematocrit value was
significantly reduced (Table I); the low hematocrit
values in the animals for hemodilution remained
after 2 days. In the 2-week group, the hematocrit
value had increased, although it was still significant-
ly lower than the initial value. At 2 days, a substan-
tial fraction of the dextran was present in the circu-
lation, whereas at 2 weeks, plasma colloid osmotic
pressure was most likely maintained by other blood
components. The reduction in hematocrit value was
more pronounced in the animals that underwent
hemodilution in combination with DDAVP.
The number of vessels that appeared fully
occluded on visual inspection at termination of the
experiments is indicated in Table I. Most of the ves-
sels in the groups for hemodilution were patent,
whereas most vessels in the control and heparin
groups were occluded.
Table I also shows the initial vena cava flow val-
ues in absolute units (milliliters per minute). These
values did not differ significantly between the
groups. We normalized the subsequent measure-
ments of vena cava flow to the initial flow value as
determined in each animal. Fig. 1 shows the relative
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vena cava flow after hemodilution (panel A), after
operation with insertion of the graft (panel B), and
at termination of the experiment at 2 days or 2
weeks, respectively (panel C). Hemodilution was
associated with a significant increase in blood flow.
At the end of the operation, after insertion of the
graft, blood flow values were generally lower in all
groups, which was most likely because of the vascu-
lar surgery.
Fig. 2, A shows the weight of the thrombus
material in the grafts after 2 days and 2 weeks. All
animals treated with hemodilution had significantly
reduced thrombus mass as compared with the con-
trols. The data from the animals that underwent
treatment with 1 bolus of heparin only did not dif-
fer from the data for the control group. However, a
single dosage of heparin in addition to hemodilution
did further decrease thrombus mass as compared
with dextran hemodilution only.
The summarized data for the whole series (Fig. 2,
panel B) reveal a negative correlation between the
flow value and the thrombus mass at termination of
the experiment. The data from the group that under-
went hemodilution in combination with heparin,
which had the highest flow and lowest thrombus
mass, appeared to deviate slightly from the relation-
ship and had a comparatively high blood flow.
DISCUSSION
Small-diameter (3 mm) PTFE grafts were insert-
ed successfully in the infrarenal vena cava of rabbits.
In control animals that did not receive hemodilution
Fig 1. Blood flow in vena cava in control group (C) and in animals that underwent hemodi-
lution (H), heparin treatment only (Hep), hemodilution in combination with heparin
(H+Hep), or hemodilution in combination with desmopressin (H+D). Groups that underwent
hemodilution are indicated with hatched bars. Filled bars indicate groups that received hemod-
ilution in combination with heparin and that were studied for 2 weeks. Flow values are given
relative to initial value determined in each animal (n = 5-11; see Table I). A shows flow values
immediately after hemodilution. In groups without hemodilution (open bars), the flow
remained unchanged. In all groups with hemodilution, the increase in blood flow, as compared
with initial flow in each group, was significant (Student’s t-test, paired analysis). B shows flow
after declamping. No significant differences were observed between groups (Bonferroni
method). C shows flow values after 2 days and 2 weeks. Occluded vessels, when present, were
included in the calculation of mean values. Statistical differences compared with control group
are indicated (Bonferroni method).
*P < .05; **P < .01; ***P < .001.
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or other treatment, the grafts were occluded to a
high extent in 5 of 8 vessels, with large accumulation
of thrombus mass within 2 days. The animals tolerat-
ed the operation, and even when the grafts were
occluded, the survival and well-being of the animals
were not affected. This result most likely reflects the
development of an adequate collateral circulation
that bypassed the occluding vessel graft. Our flow
values of approximately 50 mL min-1 would corre-
spond to 14.5 mL min-1 kg-1, which is about 85% of
the flow in lower abdominal aortas as determined
previously (17 ml × min-1 × kg-1).1 Thus, collateral ves-
sels recruited or developed in animals with occluded
grafts can accommodate most of the flow through the
vena cava. So, the vena cava PTFE graft model pro-
vides a useful tool for investigations of the thrombo-
genic process in vessels of the venous system. 
In vivo studies on the thrombotic process in
small-diameter artificial grafts in the venous circula-
tion are sparse. The PTFE grafts inserted into the
rabbit vena cava had a greater tendency for occlusion
than similarly sized grafts inserted into the rabbit
aorta.1 This most likely reflects a general difference
between the venous and arterial systems with regard
to thrombogenesis. In PTFE grafts (5-mm long
with a 2-mm inner diameter) inserted into the vena
cava of the rat, high patency rates have been
noted.15 In rat femoral veins, end-to-end anasto-
moses of PTFE or polyurethane grafts have been less
successful16-19 and sleeve anastomoses or the use of
a ring technique (3M precise microvascular anasto-
motic system, 3M Health Care, St. Paul, Minn) have
markedly improved patency rates.18-22
Patency of microvascular anastomoses has been
more difficult to achieve in the rabbit without
antithrombotic medication.23-26 In 1 study on the
rabbit, Watase et al,27 inserted PTFE grafts into the
aorta and vena cava. Although no flow values were
given, both aorta and venous vessels were reported
to be patent up to 28 days. This degree of patency
appears higher than in the present study in which
both an increased thrombus mass and a reduced
flow was observed in the control vena cava grafts
(Fig. 2, B). The difference in patency rates between
studies may reside in the experimental and surgical
procedures or in techniques for evaluating the
thrombus mass and patency rates. In the study by
Watase et al,27 the venous grafts had more thrombus
formation as compared with the aortic grafts and
were covered with thrombus material within 3 days.
The material in the venous grafts, as determined in
the present study within 2 days, was also thrombus
material, but this has been proposed to constitute an
initial step in the development of a pseudo intima or
hyperplasia. However, in most control animals, the
process instead leads to a narrowing of the lumen, a
reduced flow, and often a thrombotic occlusion. 
The increase in blood flow after isovolemic
hemodilution—about 40% compared with the initial
flow—agrees well with previously reported values for
arterial vessels in the rabbit.1,14 This shows, not sur-
prisingly, that hemodilution also increased the flow
Table I. Animal weight, hematocrit values, and vena cava blood flow values in control groups and in ani-
mals that underwent hemodilution, hemodilution in combination with heparin, and hemodilution in com-
bination with desmopressin
Hemodilution + Hemodilution + Hemodilution +
Control Hemodilution heparin Heparin desmopressin heparin 
(2 days) (2 days) (2 days) (2 days) (2 days) (2 weeks)
Animal weight (kg) 3.3 ± 0.2 (8) 3.4 ± 0.1 (8) 3.7 ± 0.1 (10) † 3.5 ± 0.1 (8) 3.5 ± 0.1 (9) 3.3 ± 0.1 (7)†
HCr, initial (%) 39.6 ± 0.7 (8) 39.2 ± 1.1 (7) 40.0 ± 1.0 (7) 38.1 ± 1.6 (8) 38.1 ± 0.4 (9) 40.3 ± 1.1 (7)
HCr, after hemo- 38.4 ± 1.1 (8) 30.0 ± 0.8 (7)*** 29.3 ± 0.5 (7)*** 38.1 ± 1.6 (8) 22.9 ± 2.7 (9)*** 27.3 ± 1.3 (6)***
dilution (%)
HCr, 2 days/ 37.8 ± 1.1 (8) 31.3 ± 0.7 (7)** 28.3 ± 0.6 (10)*** 33.6 ± 1.7 (8)* 25.6 ± 0.7 (9)*** 36.0 ± 1.6 (7)*
2 weeks (%)
Flow, initial 59.3 ± 6.3 (7) 43.5 ± 5.4 (8) 54.3 ± 4.4 (10) 50.3 ± 3.6 (8) 51.6 ± 6.1 (9) 62.4 ± 9.9 (7)
(mL/min)
Occlusion 5/8 3/8 0/10 6/8 1/9 0/7
Hematocrit (HCr) values were determined at the start of the experiments, after hemodilution, and at the end of the experiments (after
2 days or 2 weeks). The relative number of occluded grafts at the termination of the experiments is indicated. Unpaired Student’s t-test
was used, and no statistical differences were observed between the groups with regard to animal weight, initial hematocrit, and inital
blood flow. One exception was seen for animal weight in the 2 groups that underwent hemodilution and heparin (†); a P < .05 differ-
ence was observed. Statistical differences between the initial hematocrit values and the values after hemodilution and at termination of
experiments were evaluated with the Bonferroni method (*P < .05, **P < .01, ***P < .001). The occlusion rate was significantly dif-
ferent between groups (P < .01; c 2 test)
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through the veins. The likely explanation for the
increase in flow is the decreased resistance because
of the lower hematocrit value.28 The amount of
thrombus material in the grafts was reduced signif-
icantly by the dextran hemodilution. This was also
associated with an improved flow through the
grafts. The low flow in the control animals after 2
days most likely reflects a resistance introduced by
the thrombus formation in the graft. In the groups
treated with hemodilution, the higher flow at day 2
could be the result of less thrombus formation or a
lower peripheral resistance, caused by persisting
hemodilution effects. We cannot, however, clarify
to what extent an increased flow is involved in the
decrease of thrombus formation in the animals
treated with hemodilution. We previously have
shown that isovolemic hemodilution with dextran
and albumin were equally effective in increasing the
flow through artificial grafts inserted in the aorta of
rabbits.1 However, the formation of thrombus
material in the grafts was inhibited only in the dex-
tran group. This is consistent with findings that
dextran has direct effects on platelets, the coagula-
tion cascade, and fibrinolysis.4,6-9 Shoenfeld et al29
have directly shown that low-molecular-weight
dextran inhibits the platelet and fibrinogen deposi-
tion on PTFE and Dacron grafts inserted in the
venous femoral blood stream of baboons. Our
results show that a clear inhibiting effect of dextran
on thrombus formation in artificial grafts in the
Fig 2. A shows thrombus mass in controls (C) and in animals that received hemodilution (H),
heparin treatment only (Hep), hemodilution in combination with heparin (H+Hep), or hemo-
dilution in combination with desmopressin acetate (H+D). Groups that underwent hemodilu-
tion are indicated with hatched bars. Filled bars indicate groups that underwent hemodilution
in combination with heparin and that were studied for 2 weeks. The thrombus mass was sig-
nificantly lower in all groups that underwent hemodilution as compared with the control
group. Weight in the group that underwent hemodilution in combination with heparin was
significantly less than in the group that underwent hemodilution (†). No statistically signifi-
cant differences were observed between groups that underwent hemodilution and groups that
underwent hemodilution in combination with desmopressin. Statistical comparisons were
made with the Bonferroni method. In B, thrombus mass (from A) is plotted against flow (data
from C in Fig 1; n = 5-11).
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venous circulation is thus most likely caused by a
direct effect on the thrombotic process. 
Dextran has been shown to reduce the blood lev-
els and platelet aggregation activity of factor
VIIIR:Ag or von Willebrand’s factor, which leads to
prolonged bleeding times.5,10-13 DDAVP has the
opposite effect and causes an increase in the levels of
factor VIII coagulant activity, an increase in the von
Willebrand’s factor, and a shortened bleeding time
in human beings.12,13,30-32 In a study on human vol-
unteers by Lethagen et al,12 DDAVP was shown to
reverse the dextran effects on platelet adhesiveness.
Both dextran and DDAVP reduced hematocrit val-
ues and increased fibrinolytic activity. Because a dex-
tran-induced reduction in factor VIIIR:Ag could be
responsible for some of the effects of dextran on
thrombus formation in the artificial vessel grafts, we
performed experiments in animals that underwent
DDAVP treatment in combination with dextran
hemodilution. The hematocrit value in the group
that underwent DDAVP treatment was lower than
in the corresponding group that underwent hemo-
dilution only (Table I). The result reflects additive
effects of dextran and DDAVP on the hematocrit
value12,13 and shows that the DDAVP is active.
DDAVP in this concentration has been shown to
reduce bleeding time in rabbits that underwent
hirudin treatment.33 DDAVP did not counteract the
beneficial effects of dextran hemodilution with
regards to flow and thrombus mass in the vena cava
grafts. DDAVP would increase factor VIII, so the
dextran effects on the thrombus formation are pos-
sibly not caused by a reduction in the factor VIII sys-
tem. Possibly, the effects of dextran on the fibri-
nolytic activity are involved. It has been suggested
that the combination of dextran and DDAVP would
be beneficial during surgery because DDAVP would
counteract the dextran-induced prolonged bleeding
time without reducing the effect of dextran on the
fibrinolysis.12,13 Our results suggest that DDAVP,
when used in combination with dextran hemodilu-
tion, does not increase the risk of thrombus forma-
tion, even in the highly thrombus-prone artificial
grafts in the venous system. 
Superior results, with regards to graft flow and
inhibition of thrombus formation at 2 days, were
obtained with a combination of isovolemic hemodi-
lution and 1 bolus injection of heparin. Prolonged
systemic or local heparin treatments improved the
patency rates of venous grafts.2,3 In our study, a
bolus injection of heparin alone did not influence
the thrombus formation or the patency of the ves-
sels. This is consistent with other results34 and with
those from Itoh et al,2 who found occlusion of
Tetron grafts in rabbit vena cava within 2 hours after
a single bolus injection of heparin. Interestingly, our
results revealed additive effects between isovolemic
hemodilution with dextran and 1 bolus injection of
heparin. Because the thrombus material observed in
the group treated with hemodilution was further
reduced by the heparin injection, the critical time for
thrombus formation would be approximately the
initial hour after the start of reperfusion. If the ini-
tial events in the thrombus formation on the graft
surface can be inhibited, the graft is integrated in the
vasculature and remains patent for longer periods
when the dextran effects have subsided.
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